Director Michael Schmertzler filed a statement of changes in beneficial ownership with the SEC on September 11, 2026, reporting three dispositions of PTC Therapeutics, Inc. common stock executed on September 9 and September 10, 2026, under a Rule 10b5-1 plan.

Key Highlights

  • Reporting person: Michael Schmertzler, a director of PTC Therapeutics, Inc. (NASDAQ:PTCT)
  • First transaction (Sept. 9): 9,428 shares disposed at a weighted average price of $67.79 per share, with individual trades ranging from $67.54 to $68.52
  • Second transaction (Sept. 9): 572 shares disposed at a weighted average price of $68.67 per share, with individual trades ranging from $68.54 to $68.76
  • Third transaction (Sept. 10): 10,000 shares disposed at a weighted average price of $67.34 per share, with individual trades ranging from $66.84 to $67.66
  • Remaining indirect beneficial ownership: 1,316,594 shares following all three reported transactions
  • 10b5-1 plan: All transactions were executed pursuant to a written Rule 10b5-1 plan adopted on May 14, 2026

Details of Schmertzler's Share Dispositions at PTC Therapeutics

According to the filing, all three transactions were made on behalf of Section Six Partners, L.P., an entity in which Schmertzler serves as both a general partner and a limited partner. The shares are reported as indirectly held, and the filing states that Schmertzler "disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein." All sales were coded "S" in Table I, indicating open-market dispositions.

The filing notes that each transaction involved multiple trades executed at varying prices within the stated ranges, and that the prices listed represent weighted averages. Schmertzler undertakes, upon request by SEC staff, the issuer, or a security holder, to provide full information regarding the number of shares sold at each separate price. PTC Therapeutics is a biopharmaceutical company; the filing identifies it by its NASDAQ ticker symbol PTCT and lists its address as 500 Warren Corporate Center Drive, Warren, New Jersey 07059. The Form 4 was signed by Avraham S. Adler as Attorney-in-Fact on September 11, 2026.

What Was Disclosed

The filing disclosed three open-market sales of PTC Therapeutics common stock by director Michael Schmertzler on September 9 and 10, 2026, all executed through Section Six Partners, L.P. under a pre-established Rule 10b5-1 plan adopted May 14, 2026, leaving indirect beneficial ownership of 1,316,594 shares.